Results from RELAY showed that a combination of the antiangiogenic agent ramucirumab with EGFR-TKI targeted therapy provided significant and similar clinical benefit for both EGFR ex19del and ex21L858R NSCLC, and its subgroup analyses showed that in patients with co-mutations of EGFR and TP53, ramuzumab plus erlotinib showed better PFS treatment advantage than erlotinib alone (P<0.001) (85). Here, EGFR is linked to non-small cell lung carcinoma.